XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Segment information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment information

12. Segment information

 

The Company operates and manages its business as one reportable and operating segment dedicated to biopharmaceutical research and development company specializing in oncology. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on consolidated net income (loss).

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

Schedule of significant segment expenses          
   Year ended
December 31,		 
   2024   2023 
Revenue  $–   $– 
           
Less:          
Research and development   (191,000)   (203,000)
Payroll and related   (296,000)   (94,000)
Share-based compensation   (292,000)   (37,000)
Consulting related to intellectual property   (439,000)   (248,000)
Insurance   (77,000)   (76,000)
Operating expenses   (281,000)   (233,000)
Interest expense   (358,000)   (333,000)
Net loss  $(1,934,000)  $(1,224,000)